By:
On:
In: VIEWS

The Supreme Court clipped presidential power. Has the market celebrated too quickly? The U.S. Supreme Court may have dismantled the emergency tariff regime, but the trade war narrative is far from over. Within hours of the ruling, President Donald Trump moved swiftly to impose a 15% global tariff under SectionContinue Reading

By:
On:
In: SECTOR REVIEW

Rural revival, GST cuts, and favorable commodity costs drive volume recovery;  but what next for stocks  The beleaguered fast-moving consumer goods sector is showing its first convincing signs of revival after years of volume stagnation, margin pressure, and rural demand weakness. But investors betting on the recovery may already beContinue Reading

By:
On:
In: STOCKS

Company acquires 55% stake in German heart device maker Occlutech Alkem Laboratories is acquiring up to 55% of German cardiovascular device specialist Occlutech for approximately EUR 99 million (Rs 1,060 crore) as it builds out a global MedTech business targeting Rs 15,000 crore in revenues within five years. The questionContinue Reading

By:
On:
In: STOCKS

Aerospace and energy component maker’s calibrated growth strategy and peak utilization by FY28 drive buy ratings despite near-term moderation, Q3 EBITDA margin hits 39.2% India’s deepening integration into global aerospace has driven Azad Engineering into the frontline. Brokerages are upgrading or maintaining buy ratings based on a Rs 6,500 croreContinue Reading

By:
On:
In: EQUITIES

Investment bank turns bullish on Indian equities after 2025 underperformance, cites valuation compression to 10-year average, trade deal boost, and expected return of foreign flows as key catalysts Goldman Sachs Asset Management has turned constructive on Indian equities after the market’s underperformance in 2025, citing improved valuations, rebounding corporate earnings,Continue Reading

By:
On:
In: IPOS

India’s fertility treatment market leader seeks Rs 90 crore for expansion as medical tourism set to increasae Gaudium IVF and Women Health Ltd. is tapping the capital markets with a Rs 165 crore initial public offering, positioning itself as India’s first pure-play listed fertility treatment company. The issue, which opensContinue Reading